DK2662094T3 - Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere - Google Patents
Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere Download PDFInfo
- Publication number
- DK2662094T3 DK2662094T3 DK13167148.9T DK13167148T DK2662094T3 DK 2662094 T3 DK2662094 T3 DK 2662094T3 DK 13167148 T DK13167148 T DK 13167148T DK 2662094 T3 DK2662094 T3 DK 2662094T3
- Authority
- DK
- Denmark
- Prior art keywords
- cylodextrin
- formulation
- proteasome inhibitors
- peptide proteasome
- complexation methods
- Prior art date
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- 238000010668 complexation reaction Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644122P | 2012-05-08 | 2012-05-08 | |
| US201361777475P | 2013-03-12 | 2013-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2662094T3 true DK2662094T3 (da) | 2024-07-08 |
Family
ID=48326170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13167148.9T DK2662094T3 (da) | 2012-05-08 | 2013-05-08 | Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10159746B2 (da) |
| EP (2) | EP4410374A3 (da) |
| JP (1) | JP6410264B2 (da) |
| KR (5) | KR20200130748A (da) |
| CN (2) | CN104411334A (da) |
| AU (2) | AU2013259573B2 (da) |
| CA (1) | CA2873044C (da) |
| CL (1) | CL2014003055A1 (da) |
| DK (1) | DK2662094T3 (da) |
| EA (1) | EA033614B1 (da) |
| ES (1) | ES2981576T3 (da) |
| FI (1) | FI2662094T3 (da) |
| HK (2) | HK1207827A1 (da) |
| HR (1) | HRP20240724T1 (da) |
| HU (1) | HUE066956T2 (da) |
| IL (1) | IL235553B (da) |
| LT (1) | LT2662094T (da) |
| MX (2) | MX364393B (da) |
| PL (1) | PL2662094T3 (da) |
| PT (1) | PT2662094T (da) |
| RS (1) | RS65647B1 (da) |
| SG (2) | SG11201407337QA (da) |
| SI (1) | SI2662094T1 (da) |
| SM (1) | SMT202400264T1 (da) |
| WO (1) | WO2013169897A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104411334A (zh) | 2012-05-08 | 2015-03-11 | 欧尼斯治疗公司 | 用于配制肽蛋白酶体抑制剂的环糊精络合法 |
| US20160166632A1 (en) | 2013-07-19 | 2016-06-16 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
| CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
| FI3478670T3 (fi) | 2016-06-29 | 2023-05-04 | Kezar Life Sciences | Peptidi-epoksiketoni-immunoproteasomi-estäjän kiteiset suolat |
| IL263771B2 (en) | 2016-06-29 | 2023-09-01 | Kezar Life Sciences | Preparation process of immunoproteasome epoxytone peptide inhibitor and its precursors |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| HUE057221T2 (hu) | 2016-11-29 | 2022-04-28 | Oculis SA | Szilárd ciklodextrin komplexek készítményei szemészetileg aktív gyógyászati hatóanyag adagolásához |
| US20180318249A1 (en) * | 2017-05-03 | 2018-11-08 | Cydex Pharmaceuticals, Inc. | Composition containing cyclodextrin and busulfan |
| SI3993807T1 (sl) | 2019-07-01 | 2026-04-30 | Oculis Operations Sarl | Postopek za stabiliziranje ph vodnega sestavka, ki obsega zdravilo |
| CN110882221B (zh) * | 2019-11-29 | 2021-06-29 | 健进制药有限公司 | 一种注射用卡非佐米冻干制剂的生产工艺 |
| CA3145107A1 (en) * | 2020-04-09 | 2021-10-14 | Yue Jing | Bendamustine and cyclodextrin composition and use thereof |
| WO2022159319A2 (en) * | 2021-01-19 | 2022-07-28 | Mountain Valley Md Inc | A porous aluminum nanoparticulate structure |
| KR20260007821A (ko) * | 2024-07-08 | 2026-01-15 | (주) 에빅스젠 | 이마티닙을 포함하는 점안용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870060A (en) | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE19505263A1 (de) | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| DK0889056T3 (da) | 1997-07-01 | 2006-07-17 | Pfizer Prod Inc | Process for making a cyclodextrin |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| US20040106539A1 (en) | 2000-10-12 | 2004-06-03 | Ulrich Schubert | Agents for the treatment of viral infections |
| JP2003063965A (ja) | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| BRPI0418276B8 (pt) * | 2003-12-31 | 2021-05-25 | Cydex Pharmaceuticals Inc | formulação líquida inalável compreeendendo budesonida |
| JP5616569B2 (ja) | 2004-04-15 | 2014-10-29 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 酵素阻害のための化合物 |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CN101180071A (zh) | 2004-12-07 | 2008-05-14 | 普罗特奥里克斯公司 | 抑制蛋白酶体的组合物 |
| KR20080068136A (ko) * | 2005-11-15 | 2008-07-22 | 백스터 인터내셔널 인코포레이티드 | 리폭시게나제 억제제 및 시클로덱스트린을 포함하는 조성물 |
| EA018973B1 (ru) | 2007-10-04 | 2013-12-30 | Оникс Терапьютикс, Инк. | Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| BRPI0919668A2 (pt) | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
| EP2560647B1 (en) | 2010-04-19 | 2016-04-13 | Niiki Pharma Inc. | Combination therapy with a proteasome inhibitor and a gallium complex |
| HK1211311A1 (en) | 2012-02-28 | 2016-05-20 | 锡德克斯药物公司 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| WO2013169282A1 (en) | 2012-05-08 | 2013-11-14 | Onyx Therapeutics, Inc. | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
| CN104411334A (zh) | 2012-05-08 | 2015-03-11 | 欧尼斯治疗公司 | 用于配制肽蛋白酶体抑制剂的环糊精络合法 |
| HK1213585A1 (zh) | 2012-10-22 | 2016-07-08 | Cydex Pharmaceuticals, Inc. | 烷基化环糊精组合物及其制备和使用方法 |
-
2013
- 2013-05-08 CN CN201380036466.0A patent/CN104411334A/zh active Pending
- 2013-05-08 KR KR1020207032107A patent/KR20200130748A/ko not_active Ceased
- 2013-05-08 CA CA2873044A patent/CA2873044C/en active Active
- 2013-05-08 MX MX2014013552A patent/MX364393B/es active IP Right Grant
- 2013-05-08 EP EP24170493.1A patent/EP4410374A3/en active Pending
- 2013-05-08 PT PT131671489T patent/PT2662094T/pt unknown
- 2013-05-08 SG SG11201407337QA patent/SG11201407337QA/en unknown
- 2013-05-08 PL PL13167148.9T patent/PL2662094T3/pl unknown
- 2013-05-08 CN CN201710866757.2A patent/CN107693772A/zh active Pending
- 2013-05-08 DK DK13167148.9T patent/DK2662094T3/da active
- 2013-05-08 KR KR1020227020311A patent/KR20220088949A/ko not_active Ceased
- 2013-05-08 SI SI201332084T patent/SI2662094T1/sl unknown
- 2013-05-08 WO PCT/US2013/040127 patent/WO2013169897A1/en not_active Ceased
- 2013-05-08 EA EA201491994A patent/EA033614B1/ru not_active IP Right Cessation
- 2013-05-08 RS RS20240704A patent/RS65647B1/sr unknown
- 2013-05-08 HR HRP20240724TT patent/HRP20240724T1/hr unknown
- 2013-05-08 EP EP13167148.9A patent/EP2662094B1/en active Active
- 2013-05-08 KR KR1020247025639A patent/KR20240119191A/ko active Pending
- 2013-05-08 HU HUE13167148A patent/HUE066956T2/hu unknown
- 2013-05-08 JP JP2015511660A patent/JP6410264B2/ja active Active
- 2013-05-08 HK HK15108517.0A patent/HK1207827A1/xx unknown
- 2013-05-08 FI FIEP13167148.9T patent/FI2662094T3/fi active
- 2013-05-08 AU AU2013259573A patent/AU2013259573B2/en active Active
- 2013-05-08 KR KR1020147034238A patent/KR102054329B1/ko active Active
- 2013-05-08 ES ES13167148T patent/ES2981576T3/es active Active
- 2013-05-08 US US14/399,582 patent/US10159746B2/en active Active
- 2013-05-08 SM SM20240264T patent/SMT202400264T1/it unknown
- 2013-05-08 LT LTEP13167148.9T patent/LT2662094T/lt unknown
- 2013-05-08 KR KR1020197035904A patent/KR20190137963A/ko not_active Ceased
- 2013-05-08 SG SG10201609318UA patent/SG10201609318UA/en unknown
-
2014
- 2014-11-06 IL IL235553A patent/IL235553B/en active IP Right Grant
- 2014-11-07 MX MX2019004845A patent/MX2019004845A/es unknown
- 2014-11-10 CL CL2014003055A patent/CL2014003055A1/es unknown
-
2018
- 2018-01-19 AU AU2018200444A patent/AU2018200444B2/en active Active
- 2018-08-14 HK HK18110388.9A patent/HK1250927A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700109B (it) | Inibitori di istone demetilasi | |
| DK2753334T3 (da) | Fap-aktiverede proteasomhæmmere til behandling af solide tumorer | |
| DK3459942T3 (da) | DNA-PK-hæmmere | |
| DK3723369T3 (da) | Indretning til kortlægning af intraprædikationsmodus | |
| DK3777840T3 (da) | Rna-formulering til immunterapi | |
| HUE057264T2 (hu) | Eljárás új IDH1 inhibitorok elõállítására | |
| DK3454346T3 (da) | Anordning til cylotronfremstilling af technetium-99m | |
| EP2877458A4 (en) | CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| DK3311834T3 (da) | Formulering til anti-alfa4beta7-antistof | |
| DK2518585T3 (da) | Termosifonanordninger til elektroniske enheder | |
| DK2804548T3 (da) | Apparat til okklusionsfjernelse | |
| LT2895484T (lt) | Gliukozilceramido sintazės inhibitoriai | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| HUE037048T2 (hu) | Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására | |
| ZA201207384B (en) | Cylodextrin complexation methods for furmulating peptide proteasome inhibitors | |
| EP2877457A4 (en) | CYSTATHIONIN-LYASE (CSE) INHIBITORS | |
| EP2917210A4 (en) | KINASE INHIBITORS | |
| DK3300610T3 (da) | Fremgangsmåde til fraktionering af opløselige ærter | |
| EP2785183A4 (en) | TRIAZOLPYRIDINON PDE10 INHIBITORS | |
| DK2485011T3 (da) | Anordning til måling af afbøjningen af en genstand | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| EP2661633A4 (en) | PROOF OF PROTEOLYSIS | |
| DK2834229T3 (da) | Fremgangsmåde til fremstilling af ccr3-inhibitorer | |
| EP2858975A4 (en) | FBXO3 INHIBITORS |